Medicines known as GLP-1 receptor agonists have become widely known for helping people lose weight.
Drugs such as semaglutide and tirzepatide can reduce appetite, help people eat less, and lead to substantial weight loss.
Scientists are now discovering that these medicines may also improve health in ways that go beyond reducing body weight.
A new analysis presented at the International Congress on Obesity 2026 suggests they may strongly reduce inflammation throughout the body, which could help explain why they lower the risk of heart disease.
The study was led by researchers from the National Institute of Cardiology Ignacio Chavez in Mexico City and was presented at the International Congress on Obesity, hosted by the World Obesity Federation.
The research combined evidence from 10 high-quality randomized controlled trials involving more than 23,000 adults without diabetes. By pooling many studies together, researchers were able to obtain a clearer picture of the medicines’ overall effects.
Inflammation is the body’s natural response to injury or infection. However, obesity can trigger a constant low level of inflammation that continues for many years. This ongoing inflammation damages blood vessels and organs and increases the risk of heart disease, stroke, kidney disease, and other long-term health problems.
To measure inflammation, doctors often use a blood marker called high-sensitivity C-reactive protein, or hsCRP. Higher hsCRP levels are linked with a greater chance of future cardiovascular disease. Lowering this marker is generally considered a positive sign that inflammation is decreasing.
The researchers searched major medical databases to find randomized clinical trials in adults without diabetes who were taking GLP-1 medicines mainly for weight management. They focused on studies that measured changes in hsCRP before and after treatment. Ten studies met the strict inclusion criteria.
The results were striking. Overall, people taking GLP-1 medicines experienced about a 45 percent reduction in hsCRP compared with those receiving a placebo. This suggests these medicines have a powerful anti-inflammatory effect that cannot be explained simply by lowering blood sugar because none of the participants had diabetes.
The greatest benefit was seen in people with obesity and related heart and metabolic conditions, where hsCRP fell by about 48 percent. Participants with heart failure with preserved ejection fraction and those with existing cardiovascular disease also experienced significant reductions of around 38 percent. Both semaglutide and tirzepatide appeared to perform similarly.
Scientists believe reducing inflammation could be one reason these medicines lower the risk of heart attacks and other cardiovascular problems. Previous studies have already shown that GLP-1 medicines improve blood pressure, cholesterol, and body weight. The new findings suggest calming inflammation may be another important part of the picture.
Although the findings are encouraging, the researchers caution that this analysis cannot prove exactly how much inflammation contributes to better health outcomes. More studies are needed to understand the biological mechanisms involved and to determine whether lowering hsCRP directly leads to fewer heart attacks or longer survival.
In review, this large meta-analysis strengthens the evidence that GLP-1 medicines provide benefits beyond weight loss. The substantial reduction in inflammation offers a possible explanation for their impressive cardiovascular effects and opens new directions for future research.
If confirmed by additional studies, these medicines may become even more important in preventing obesity-related diseases.
If you care about weight loss, please read studies that avocado could help you lose weight and belly fat, and a keto diet for weight loss can cause flu-like symptoms.
For more health information, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and these antioxidants could help reduce dementia risk.
